Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Polaris Group's Debt-to-EBITDA or its related term are showing as below:
TPE:6550'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.89 Med: -0.82 Max: -0.39
Current: -0.71
During the past 12 years, the highest Debt-to-EBITDA Ratio of Polaris Group was -0.39. The lowest was -1.89. And the median was -0.82.
TPE:6550's Debt-to-EBITDA is ranked worse than 100% of 296
companies
in the Biotechnology industry
Industry Median: 1.15
vs TPE:6550: -0.71
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Polaris Group Debt-to-EBITDA Related Terms
Polaris Group Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Polaris Group's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6550 vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Polaris Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polaris Group Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Polaris Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Polaris Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Polaris Group (TPE:6550) has a Debt-to-EBITDA of -1.33 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Polaris Group. According to the industry distribution chart, Polaris Group ranks #999999 out of 296 companies in the Biotechnology industry.
Is Polaris Group's Debt-to-EBITDA too high?
Polaris Group's current Debt-to-EBITDA is -1.33. Based on the distribution chart, Polaris Group ranks #999999 out of 296 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Polaris Group has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Polaris Group's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Polaris Group ranks #999999 out of 296 companies for Debt-to-EBITDA. This places Polaris Group in the lower half of its industry. The industry median Debt-to-EBITDA is 1.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.15, based on 296 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Polaris Group. For the Biotechnology industry, the median Debt-to-EBITDA is 1.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polaris Group's current Debt-to-EBITDA is -1.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polaris Group stock overvalued right now?
Based on GuruFocus' analysis, Polaris Group (TPE:6550) is currently considered Possible Value Trap. The stock's GF Value™ is NT$51.62, compared to a current price of NT$11.00 — trading 78.7% below its estimated fair value. The current Debt-to-EBITDA is -1.33. Polaris Group's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Polaris Group (TPE:6550), the current Debt-to-EBITDA is -1.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polaris Group (TPE:6550) Overvalued in 2026?
Based on GuruFocus' analysis, Polaris Group stock appears to be undervalued.
The current stock price of NT$11.00 is trading 78.7% below its estimated GF Value™ of NT$51.62.
GuruFocus considers Polaris Group to be Possible Value Trap.
Key valuation signals for TPE:6550:
Debt-to-EBITDA: -1.33
GF Value™: NT$51.62 vs. price of NT$11.00 (78.7% below fair value)
No single metric tells the full story. See the TPE:6550 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies. The company's lead therapeutic Pegargiminase (ADI PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Polaris Group is also involved in every stage of the drug development process.
55GF Score
Get the complete analysis for TPE:6550
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6550 has been successfully added to your 
